Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
3.305
+0.085 (2.64%)
At close: Jun 23, 2026, 4:00 PM EDT
3.270
-0.035 (-1.06%)
After-hours: Jun 23, 2026, 4:00 PM EDT
Cyclerion Therapeutics Revenue
Cyclerion Therapeutics had revenue of $1.99M in the twelve months ending March 31, 2026, down -4.23% year-over-year. In the year 2025, Cyclerion Therapeutics had annual revenue of $2.07M with 3.70% growth.
Revenue (ttm)
$1.99M
Revenue Growth
-4.23%
P/S Ratio
6.85
Revenue / Employee
$1,993,000
Employees
1
Market Cap
14.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.07M | 74.00K | 3.70% |
| Dec 31, 2024 | 2.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 297.00K | -3.65M | -92.47% |
| Dec 31, 2021 | 3.94M | 1.65M | 71.69% |
| Dec 31, 2020 | 2.30M | -2.21M | -49.06% |
| Dec 31, 2019 | 4.51M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Traws Pharma | 2.73M |
| OSR Holdings | 2.63M |
| SeaStar Medical Holding | 1.44M |
| BioLineRx | 1.40M |
| CytoMed Therapeutics | 669.28K |
| Lexaria Bioscience | 368.00K |
| Cocrystal Pharma | 225.00K |
CYCN News
- 2 months ago - Why is Cyclerion Therapeutics Stock (CYCN) Up Over 160% Today? - TipRanks
- 2 months ago - Cyclerion Therapeutics, Korsana Biosciences enter merger agreement - TheFly
- 2 months ago - Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement - Business Wire
- 4 months ago - Cyclerion receives positive written feedback, responses on CYC-126 study - TheFly
- 4 months ago - Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board - GlobeNewsWire
- 6 months ago - Cyclerion Therapeutics enters exclusive collaboration with Medsteer - TheFly
- 6 months ago - Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression - GlobeNewsWire
- 9 months ago - Cyclerion enters licensing agreement with MIT, announces strategic relaunch - TheFly